INTRODUCTION: Plasma-based circulating tumor DNA (ctDNA) is an established biomarker for molecular profiling with emerging applications in disease monitoring in multiple tumor types, including, NSCLC. However, determinants of ctDNA shedding and correlation with tumor burden are incompletely understood, particularly in advanced-stage disease. METHODS: We retrospectively analyzed ctDNA-based and tissue-based genomic data and imaging from 144 patients with NSCLC. Tumor burden was quantified with computed tomography (CT) and brain magnetic resonance imaging for the overall cohort and 18F-fludeoxyglucose positron emission tomography-CT in a subset of patients. RESULTS: There was a moderate but statistically significant correlation between ctDNA variant allele frequency and multiple imaging measures of tumor burden such as CT volume (rho = 0.34, p ≤ 0.0001) and metabolic tumor volume (rho = 0.36, p = 0.003). This correlation was strongest in KRAS-mutant tumors (rho = 0.56, p ≤ 0.001), followed by TP53 mutants (rho = 0.43, p ≤ 0.0001), and weakest in EGFR-mutated (EGFR+) tumors (rho = 0.24, p = 0.077). EGFR+ tumors with EGFR copy number gain had significantly higher variant allele frequency than EGFR+ without copy number gain (p ≤ 0.00001). In multivariable analysis, TP53 and EGFR mutations, visceral metastasis, and tumor burden were independent predictors of increased ctDNA shedding. CONCLUSIONS: Levels of detectable ctDNA were affected not only by tumor burden but also by tumor genotype. The genotype-specific differences observed may be due to variations in DNA shedding and cellular turnover. These findings have implications for the emerging use of ctDNA in NSCLC disease monitoring and early detection.
INTRODUCTION: Plasma-based circulating tumor DNA (ctDNA) is an established biomarker for molecular profiling with emerging applications in disease monitoring in multiple tumor types, including, NSCLC. However, determinants of ctDNA shedding and correlation with tumor burden are incompletely understood, particularly in advanced-stage disease. METHODS: We retrospectively analyzed ctDNA-based and tissue-based genomic data and imaging from 144 patients with NSCLC. Tumor burden was quantified with computed tomography (CT) and brain magnetic resonance imaging for the overall cohort and 18F-fludeoxyglucose positron emission tomography-CT in a subset of patients. RESULTS: There was a moderate but statistically significant correlation between ctDNA variant allele frequency and multiple imaging measures of tumor burden such as CT volume (rho = 0.34, p ≤ 0.0001) and metabolic tumor volume (rho = 0.36, p = 0.003). This correlation was strongest in KRAS-mutant tumors (rho = 0.56, p ≤ 0.001), followed by TP53 mutants (rho = 0.43, p ≤ 0.0001), and weakest in EGFR-mutated (EGFR+) tumors (rho = 0.24, p = 0.077). EGFR+ tumors with EGFR copy number gain had significantly higher variant allele frequency than EGFR+ without copy number gain (p ≤ 0.00001). In multivariable analysis, TP53 and EGFR mutations, visceral metastasis, and tumor burden were independent predictors of increased ctDNA shedding. CONCLUSIONS: Levels of detectable ctDNA were affected not only by tumor burden but also by tumor genotype. The genotype-specific differences observed may be due to variations in DNA shedding and cellular turnover. These findings have implications for the emerging use of ctDNA in NSCLC disease monitoring and early detection.
Authors: Isaac Garcia-Murillas; Gaia Schiavon; Britta Weigelt; Charlotte Ng; Sarah Hrebien; Rosalind J Cutts; Maggie Cheang; Peter Osin; Ashutosh Nerurkar; Iwanka Kozarewa; Javier Armisen Garrido; Mitch Dowsett; Jorge S Reis-Filho; Ian E Smith; Nicholas C Turner Journal: Sci Transl Med Date: 2015-08-26 Impact factor: 17.956
Authors: Rajiv Raja; Michael Kuziora; Philip Z Brohawn; Brandon W Higgs; Ashok Gupta; Phillip A Dennis; Koustubh Ranade Journal: Clin Cancer Res Date: 2018-08-09 Impact factor: 12.531
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Aadel A Chaudhuri; Jacob J Chabon; Alexander F Lovejoy; Aaron M Newman; Henning Stehr; Tej D Azad; Michael S Khodadoust; Mohammad Shahrokh Esfahani; Chih Long Liu; Li Zhou; Florian Scherer; David M Kurtz; Carmen Say; Justin N Carter; David J Merriott; Jonathan C Dudley; Michael S Binkley; Leslie Modlin; Sukhmani K Padda; Michael F Gensheimer; Robert B West; Joseph B Shrager; Joel W Neal; Heather A Wakelee; Billy W Loo; Ash A Alizadeh; Maximilian Diehn Journal: Cancer Discov Date: 2017-09-24 Impact factor: 39.397
Authors: David R Gandara; Sarah M Paul; Marcin Kowanetz; Erica Schleifman; Wei Zou; Yan Li; Achim Rittmeyer; Louis Fehrenbacher; Geoff Otto; Christine Malboeuf; Daniel S Lieber; Doron Lipson; Jacob Silterra; Lukas Amler; Todd Riehl; Craig A Cummings; Priti S Hegde; Alan Sandler; Marcus Ballinger; David Fabrizio; Tony Mok; David S Shames Journal: Nat Med Date: 2018-08-06 Impact factor: 53.440
Authors: Yuxuan Wang; Lu Li; Joshua D Cohen; Isaac Kinde; Janine Ptak; Maria Popoli; Joy Schaefer; Natalie Silliman; Lisa Dobbyn; Jeanne Tie; Peter Gibbs; Cristian Tomasetti; Kenneth W Kinzler; Nickolas Papadopoulos; Bert Vogelstein; Louise Olsson Journal: JAMA Oncol Date: 2019-08-01 Impact factor: 31.777
Authors: Joshua D Campbell; Anton Alexandrov; Jaegil Kim; Jeremiah Wala; Alice H Berger; Chandra Sekhar Pedamallu; Sachet A Shukla; Guangwu Guo; Angela N Brooks; Bradley A Murray; Marcin Imielinski; Xin Hu; Shiyun Ling; Rehan Akbani; Mara Rosenberg; Carrie Cibulskis; Aruna Ramachandran; Eric A Collisson; David J Kwiatkowski; Michael S Lawrence; John N Weinstein; Roel G W Verhaak; Catherine J Wu; Peter S Hammerman; Andrew D Cherniack; Gad Getz; Maxim N Artyomov; Robert Schreiber; Ramaswamy Govindan; Matthew Meyerson Journal: Nat Genet Date: 2016-05-09 Impact factor: 38.330
Authors: Philip C Mack; Jieling Miao; Mary W Redman; James Moon; Sarah B Goldberg; Roy S Herbst; Mary Ann Melnick; Zenta Walther; Fred R Hirsch; Katerina Politi; Karen Kelly; David R Gandara Journal: Clin Cancer Res Date: 2022-09-01 Impact factor: 13.801
Authors: Runzhe Chen; Jun Li; Junya Fujimoto; Lingzhi Hong; Xin Hu; Kelly Quek; Ming Tang; Akash Mitra; Carmen Behrens; Chi-Wan Chow; Peixin Jiang; Latasha D Little; Curtis Gumbs; Xingzhi Song; Jianhua Zhang; Dongfeng Tan; John V Heymach; Ignacio Wistuba; P Andrew Futreal; Don L Gibbons; Lauren A Byers; Jianjun Zhang; Alexandre Reuben Journal: J Exp Clin Cancer Res Date: 2022-05-11
Authors: Asad Ur Rehman; Parvez Khan; Shailendra Kumar Maurya; Jawed A Siddiqui; Juan A Santamaria-Barria; Surinder K Batra; Mohd Wasim Nasser Journal: Mol Cancer Date: 2022-05-10 Impact factor: 41.444
Authors: Xiuning Le; Lingzhi Hong; Chuck Hensel; Rongrong Chen; Haley Kemp; Niamh Coleman; Christine A Ciunci; Stephen V Liu; Marcelo V Negrao; Jennifer Yen; Xuefeng Xia; Juergen Scheuenpflug; Christopher Stroh; Dilafruz Juraeva; Anne Tsao; David Hong; Victoria Raymond; Paul Paik; Jianjun Zhang; John V Heymach Journal: JCO Precis Oncol Date: 2021-12-13